Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study.

Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR.

J Clin Pharmacol. 2011 Nov;51(11):1587-91. doi: 10.1177/0091270010387604. Epub 2011 Jan 5. No abstract available.

PMID:
21209243
2.

Strategies for successful clinical management of schizophrenia with ziprasidone.

Fagiolini A, Cañas F, Gallhofer B, Larmo I, Levy P, Montes JM, Papageorgiou G, Zink M, Rossi A.

Expert Opin Pharmacother. 2010 Sep;11(13):2199-220. doi: 10.1517/14656566.2010.507630. Review.

PMID:
20658947
3.

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.

Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.

CNS Spectr. 2009 Sep;14(9):478-86.

PMID:
19890230
4.

Ziprasidone, a new atypical antipsychotic drug.

Carnahan RM, Lund BC, Perry PJ.

Pharmacotherapy. 2001 Jun;21(6):717-30. Review.

PMID:
11401184
5.

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.

Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C.

J Clin Psychiatry. 2009 Jun;70(6):801-9.

PMID:
19573479
6.
7.

Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.

Daniel DG, Copeland LF.

Expert Opin Investig Drugs. 2000 Apr;9(4):819-28. Review.

PMID:
11060712
8.

How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.

Lincoln J, Stewart ME, Preskorn SH.

J Psychiatr Pract. 2010 Mar;16(2):103-14. doi: 10.1097/01.pra.0000369971.64908.dc.

PMID:
20511734
9.

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.

Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR.

Psychopharmacology (Berl). 1998 Nov;140(2):173-84.

PMID:
9860108
10.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
11.

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.

Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O'Gorman C, Harrigan RH.

Clin Ther. 2010 Mar;32(3):472-91. doi: 10.1016/j.clinthera.2010.03.003.

PMID:
20399985
12.

Tolerability of ziprasidone: an expanding perspective.

Daniel DG.

J Clin Psychiatry. 2003;64 Suppl 19:40-9. Review.

13.

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.

Hirsch SR, Kissling W, Bäuml J, Power A, O'Connor R.

J Clin Psychiatry. 2002 Jun;63(6):516-23.

PMID:
12088164
14.

An African patient with ziprasidone intolerance.

Hein J, Gregor A, Bartholomä A, Heinz A, Juckel G.

J Clin Psychiatry. 2005 Jun;66(6):800. No abstract available.

PMID:
15960579
15.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
16.

Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.

Miceli JJ, Wilner KD, Swan SK, Tensfeldt TG.

J Clin Pharmacol. 2005 Jun;45(6):620-30.

PMID:
15901743
17.

The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.

Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, Preskorn SH.

J Clin Psychiatry. 2009 Jan;70(1):58-62. Epub 2008 Oct 21.

PMID:
19026256
18.
19.

Low concentration of ziprasidone in human milk: a case report.

Schlotterbeck P, Saur R, Hiemke C, Gründer G, Vehren T, Kircher T, Leube D.

Int J Neuropsychopharmacol. 2009 Apr;12(3):437-8. doi: 10.1017/S1461145709009936. Epub 2009 Feb 10. No abstract available.

PMID:
19203410
20.

Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study.

Loebel AD, Khanna S, Rajadhyaksha S, Siu CO, Giller E, Potkin SG.

J Clin Psychiatry. 2007 Sep;68(9):1333-8.

PMID:
17915970

Supplemental Content

Support Center